Lenvatinib under the microscope: safety check for tough thyroid cancers

NCT ID NCT03573960

Completed Disease control Sponsor: Eisai Pharmaceuticals India Pvt. Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at the safety of the drug lenvatinib in 50 people with advanced thyroid cancer that had stopped responding to radioactive iodine treatment. Researchers tracked side effects and how often patients needed to lower their dose. They also checked whether tumors shrank or disappeared. The goal was to confirm that lenvatinib is safe enough for routine use in this hard-to-treat group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenvatinib
What this could lead to: If successful, this study could confirm lenvatinib as a safe and effective option for controlling advanced thyroid cancer that no longer responds to standard treatment.
What could go wrong: This is a small, single-arm study with no comparison group, so results may not be definitive. Side effects like high blood pressure, fatigue, and diarrhea are common and can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma Thyroid Neoplasms thyroid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID NEOPLASMS

Contacts and locations

Locations

All India Institute of Medical Sciences

New Delhi, National Capital Territory of Delhi, 110029, India
All India Institute of Medical Sciences

Bhubaneswar, Odisha, 751019, India
BL Kapoor Hospital, New Delhi

New Delhi, 110005, India
City Cancer Centre

Vijayawada, 520002, India
Deenanath Mangeshkar Hospital

Pune, Maharashtra, 411004, India
Indraprastha Apollo Hospital

New Delhi, National Capital Territory of Delhi, 110076, India
Indrayani Hospital, Alandi

Pune, 412105, India
Regional Cancer Centre, RCC, Thiruvananthapuram

Thiruvananthapuram, Kerala, 695011, India
S. P. Medical College & A. G. Hospitals

Bikaner, Rajasthan, 334003, India
Shetty's Hospital

Bangalore, Karnataka, 560068, India
Tata Memorial Hospital

Mumbai, 400012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.